Less - current portion of these notes

$ 181,000

$ 258,000

Less - note discounts

(1,858)

(3,153)

(179,142)

(254,847)

Total notes payable and convertible notes, net discounts

Alternative Strategy Partners PTE Ltd.- Sep 2015 [Member]

GS Capital Partners LLC - Oct 2017 [Member]

^[1]

90,000

GS Capital Partners LLC - March 2018 [Member]

^[2]

105,000

GS Capital Partners LLC - May 2018 [Member]

^[3]

48,000

Note to an Individual - Feb 2013 [Member]

^[4]

28,000

^[5]

$ 15,000

[1]	Three-month $180,000 non-convertible debenture ("note") dated September 23, 2015 bearing and interest rate of 11.50% per annum. The note matured in December 2015. The Company received cash of $90,000 ($75,000 wired directly to the Company and $15,000 wired directly from ASP to compensate a consultant). The balance of this note ($90,000) was to be wired directly to a Japanese based consumer product firm called Eishin, Inc., but the holder never provided any documentation evidencing that $90,000 was paid to Eishin. The Company is in dispute with the noteholder, and the Company has not recorded this liability as of June 30, 2018 or March 31, 2018. If the proper documentation is provided to the Company, the Company will record the liability at that time. The Company has not received any type of default notice with respect to this $180,000 non-convertible note. Additionally, the Company has not received any shares in Eishin Co., Ltd. up to this point. The Company did follow up with Eishin in March 2017, and it was noted that Eishin did not reflect the Company as having this ownership. As a result, the additional $90,000 has not been recognized as outstanding. As of June 30, 2018, this note had accrued interest of $23,468.
[2]	On October 17, 2017, the Company entered into a stock purchase agreement with GS Capital Partners LLC, whereby the Company issued two 8% convertible redeemable notes each in the principal amount of $105,000. The first 8% note was funded with gross cash proceeds of $100,000, after the deduction of $5,000 in legal fees. The second 8% note (the “Back-End Note”) was initially paid for by an offsetting promissory note issued by GS Capital Partners LLC, to the Company (the “Note Receivable”). The terms of the Back-End Note require cash funding prior to any conversion thereunder. The amounts of cash funded plus accrued interest under both the First Note and the Back-End Note are convertible into shares of the Company’s common stock at a price per share equal to 70% of the lowest daily VWAP of the common stock as reported on the National Quotations Bureau OTC Markets market on which the Company’s shares are traded or any exchange upon which the common stock may be traded in the future, for the 15 prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. In the event the Company experiences a DTC “chill” on its shares, the conversion price shall be decreased to 60% instead of 70% while that “chill” is in effect. Upon an event of default, principal and accrued interest will become immediately due and payable under the notes. Additionally, upon an event of default, both notes will accrue interest at a default interest rate of 24% per annum or the highest rate of interest permitted by law. Further, certain events of default may trigger penalty and liquidated damage provisions. During the first 6 months that the First Note and the Back-End Note are outstanding, the Company may redeem either by paying to GS Capital Partners LLC an amount as follows: (i) if the redemption is within the first 90 days either note is in effect, then for an amount equal to 120% of the unpaid principal amount of either note along with any interest that has accrued during that period, and (ii) if the redemption is after the 91st day the either note is in effect, but less than the 180th day, then for an amount equal to 133% of the unpaid principal amount of either note along with any accrued interest. Neither note may be redeemed after 180 days. Additionally, and pursuant to the Purchase Agreement, the Company issued to GS Capital Partners LLC 306,667 shares of the Company’s common stock valued at $20,700 ($0.0675 per share). On April 25, 2018, the noteholder, under their rights under the contract, canceled the back-end note. On May 1, 2018, the noteholder converted $55,000 of principal and accrued interest of $2,339 in exchange for 1,985,754 of the Company’s shares ($0.028888 per share). On July 18, 2018, the Company paid $69,503 to fully retire the remaining $50,000 principal balance of this note plus $3,503 of accrued interest and a prepayment penalty of $16,500.
[3]	On March 9, 2018, GS Capital Partners, LLC funded the back-end note under the August 31, 2017 Securities Purchase Agreement with GS Capital Partners, LLC whereby the Company issued two 8% convertible redeemable notes each in the principal amount of $48,000. This Back-End Note was initially paid for by an offsetting promissory note issued by GS Capital Partners, LLC to the Company (the “Note Receivable”). This note has a maturity date one year from the date of issuance of the original note under the securities purchase agreement, upon which any outstanding principal and interest is due and payable. Although the note principal plus interest was not repaid by the due date, the noteholder waived the default clause. The amounts of cash funded plus accrued interest under the note are convertible into shares of the Company’s common stock at a price for each share of common stock equal to 70% of the lowest daily VWAP of the common stock as reported on the National Quotations Bureau OTC Markets market on which the Company’s shares are traded or any exchange upon which the common stock may be traded in the future, for the 15 prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. In the event the Company experiences a DTC “chill” on its shares, the conversion price shall be decreased to 60% instead of 70% while that “chill” is in effect. Upon an event of default, principal and accrued interest will become immediately due and payable under the notes. Additionally, upon an event of default, notes will accrue interest at a default interest rate of 24% per annum or the highest rate of interest permitted by law. Further, certain events of default may trigger penalty and liquidated damage provisions. During the first six months this note is in effect, the Company may redeem by paying to GS Capital Partners, LLC an amount as follows: (i) if the redemption is within the first 90 days either note is in effect, then for an amount equal to 120% of the unpaid principal amount of either note along with any interest that has accrued during that period, and (ii) if the redemption is after the 91st day the either note is in effect, but less than the 180th day, then for an amount equal to 133% of the unpaid principal amount of either note along with any accrued interest. The note may be redeemed after 180 days. At September 30, 2018, this note had accrued interest of $2,157. On October 26, 2018, the Company fully repaid this note in cash using proceeds from a new convertible note.
[4]	On May 10, 2018, the Company entered into a securities purchase agreement with GS Capital Partners, LLC. GS Capital Partners, LLC whereby the Company issued two 8% convertible redeemable notes in the cumulative principal amount of $56,000. The first 8% note for $28,000 was funded with net proceeds of $25,000, after the deduction of $3,000 for OID. The second 8% note (the Back-End Note) is initially paid for by an offsetting promissory note issued by GS Capital Partners, LLC to the Company (the Note Receivable). The terms of the Back-End Note require cash funding prior to any conversion thereunder. The Note Receivable is due January 10, 2019, unless certain conditions are not met, in which case both the Back-End Note and the Note Receivable may both be cancelled. Both the First Note and the Back-End Note have a maturity date one year from the date of issuance upon which any outstanding principal and interest is due and payable. The amounts of cash funded plus accrued interest under both the First Note and the Back-End Note are convertible into shares of the Company's common stock at a price for each share of common stock equal to 70% of the lowest daily VWAP of the common stock as reported on the National Quotations Bureau OTC Markets market on which the Company's shares are traded or any exchange upon which the common stock may be traded in the future, for the 15 prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. In the event the Company experiences a DTC chill on its shares, the conversion price shall be decreased to 60% instead of 70% while that chill is in effect. The Back-End Note will not be cash funded and such note, along with the Note Receivable, will be immediately cancelled if the shares do not maintain a minimum trading price during the five days prior to such funding and a certain aggregate dollar trading volume during such period. Upon an event of default, principal and accrued interest will become immediately due and payable under the notes. Additionally, upon an event of default, both notes will accrue interest at a default interest rate of 24% per annum or the highest rate of interest permitted by law. Further, certain events of default may trigger penalty and liquidated damage provisions. During the first six months First Note is in effect, the Company may redeem either note by paying to GS Capital Partners, LLC an amount as follows: (i) if the redemption is within the first 90 days either note is in effect, then for an amount equal to 120% of the unpaid principal amount of either note along with any interest that has accrued during that period, and (ii) if the redemption is after the 91st day the either note is in effect, but less than the 180th day, then for an amount equal to 133% of the unpaid principal amount of either note along with any accrued interest. The note may be redeemed after 180 days. The back-end note may not be repaid. The note holder may redeem this note at any time after the first six months. The Company had cancelled all remaining back-end notes during the quarter ended September 30, 2018. As of September 30, 2018, this note had accrued interest of $1,123. On October 26, 2018, the Company fully repaid this note in cash using proceeds from a new convertible note.
[5]	An individual note was issued on February 22, 2013, in the amount of $15,000, bearing an interest rate of 8%. The note is convertible into common stock of the Company at $1.875 per share. As of June 30, 2018, this note accrued interest of $6,723.

XML 55 R40.htm IDEA: XBRL DOCUMENT

Notes Payable and Convertible Notes - Schedule of Notes Payable to Individuals and Companies (Details) (Parenthetical) - USD ($)								6 Months Ended		9 Months Ended
	Jul. 18, 2018	May 10, 2018	May 10, 2018	May 01, 2018	Mar. 09, 2018	Oct. 17, 2017	Sep. 23, 2015	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Feb. 22, 2013
Accrued interest								$ 7,026		$ 7,026
Gross proceeds from convertible debt								25,000	$ 376,100
Legal fees									$ 19,900
Convertible note, default rate											8.00%
GS Capital Partners LLC [Member] \| First 8% Convertible Redeemable Notes [Member] \| Stock Purchase Agreements [Member]
Debt principal amount		$ 56,000	$ 56,000		$ 48,000	$ 105,000
Debt instrument, interest rate		8.00%	8.00%		8.00%	8.00%
Gross proceeds from convertible debt		$ 28,000				$ 100,000
Legal fees						5,000
Original issue of discount		3,000	$ 3,000
Net proceeds from convertible debt		25,000
GS Capital Partners LLC [Member] \| Second 8% Convertible Redeemable Notes [Member] \| Stock Purchase Agreements [Member]
Debt principal amount		$ 56,000	$ 56,000		$ 48,000	$ 105,000
Debt instrument, interest rate		8.00%	8.00%		8.00%	8.00%
Notes maturity date			Jan. 10, 2019
Non-Convertible Debenture [Member]
Debt principal amount							$ 180,000
Debt instrument, interest rate							11.50%
Debt maturity date description							The note matured in December 2015
Proceeds from notes payable							$ 90,000
Accrued interest								23,468		23,468
Non-Convertible Debenture [Member] \| Consultant [Member]
Proceeds from notes payable							15,000
Non-Convertible Debenture [Member] \| Company [Member]
Proceeds from notes payable							75,000
Non-Convertible Debenture [Member] \| Eishin, Inc [Member]
Proceeds from notes payable							$ 90,000
First Note and Back-End Note [Member] \| GS Capital Partners LLC [Member] \| Stock Purchase Agreements [Member]
Debt principal amount	$ 50,000
Accrued interest	3,503							2,157		2,157
Percentage of share price multiplied by the lowest closing price		70.00%			70.00%	70.00%
Debt conversion, description		The amounts of cash funded plus accrued interest under both the First Note and the Back-End Note are convertible into shares of the Company's common stock at a price for each share of common stock equal to 70% of the lowest daily VWAP of the common stock as reported on the National Quotations Bureau OTC Markets market on which the Company's shares are traded or any exchange upon which the common stock may be traded in the future, for the 15 prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. In the event the Company experiences a DTC "chill" on its shares, the conversion price shall be decreased to 60% instead of 70% while that "chill" is in effect. The Back-End Note will not be cash funded and such note, along with the Note Receivable, will be immediately cancelled if the shares do not maintain a minimum trading price during the five days prior to such funding and a certain aggregate dollar trading volume during such period. Upon an event of default, principal and accrued interest will become immediately due and payable under the notes. Additionally, upon an event of default, both notes will accrue interest at a default interest rate of 24% per annum or the highest rate of interest permitted by law. Further, certain events of default may trigger penalty and liquidated damage provisions. During the first six months First Note is in effect, the Company may redeem either note by paying to GS Capital Partners, LLC an amount as follows: (i) if the redemption is within the first 90 days either note is in effect, then for an amount equal to 120% of the unpaid principal amount of either note along with any interest that has accrued during that period, and (ii) if the redemption is after the 91st day the either note is in effect, but less than the 180th day, then for an amount equal to 133% of the unpaid principal amount of either note along with any accrued interest. The note may be redeemed after 180 days.			The amounts of cash funded plus accrued interest under the note are convertible into shares of the Company's common stock at a price for each share of common stock equal to 70% of the lowest daily VWAP of the common stock as reported on the National Quotations Bureau OTC Markets market on which the Company's shares are traded or any exchange upon which the common stock may be traded in the future, for the 15 prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. In the event the Company experiences a DTC "chill" on its shares, the conversion price shall be decreased to 60% instead of 70% while that "chill" is in effect. Upon an event of default, principal and accrued interest will become immediately due and payable under the notes. Additionally, upon an event of default, notes will accrue interest at a default interest rate of 24% per annum or the highest rate of interest permitted by law. Further, certain events of default may trigger penalty and liquidated damage provisions. During the first six months this note is in effect, the Company may redeem by paying to GS Capital Partners, LLC an amount as follows: (i) if the redemption is within the first 90 days either note is in effect, then for an amount equal to 120% of the unpaid principal amount of either note along with any interest that has accrued during that period, and (ii) if the redemption is after the 91st day the either note is in effect, but less than the 180th day, then for an amount equal to 133% of the unpaid principal amount of either note along with any accrued interest. The note may be redeemed after 180 days.	The amounts of cash funded plus accrued interest under both the First Note and the Back-End Note are convertible into shares of the Company's common stock at a price per share equal to 70% of the lowest daily VWAP of the common stock as reported on the National Quotations Bureau OTC Markets market on which the Company's shares are traded or any exchange upon which the common stock may be traded in the future, for the 15 prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. In the event the Company experiences a DTC "chill" on its shares, the conversion price shall be decreased to 60% instead of 70% while that "chill" is in effect. Upon an event of default, principal and accrued interest will become immediately due and payable under the notes. Additionally, upon an event of default, both notes will accrue interest at a default interest rate of 24% per annum or the highest rate of interest permitted by law. Further, certain events of default may trigger penalty and liquidated damage provisions. During the first 6 months that the First Note and the Back-End Note are outstanding, the Company may redeem either by paying to GS Capital Partners LLC an amount as follows: (i) if the redemption is within the first 90 days either note is in effect, then for an amount equal to 120% of the unpaid principal amount of either note along with any interest that has accrued during that period, and (ii) if the redemption is after the 91st day the either note is in effect, but less than the 180th day, then for an amount equal to 133% of the unpaid principal amount of either note along with any accrued interest. Neither note may be redeemed after 180 days.
Number of common stock shares issued						306,667
Number of common stock issued						$ 20,700
Shares issued price per share						$ 0.0675
Payments of convertible note	69,503
Prepayment penalty	$ 16,500
Convertible note, default rate					24.00%
First Note and Back-End Note [Member] \| GS Capital Partners LLC [Member] \| Stock Purchase Agreements [Member] \| Note Holders [Member]
Accrued interest				$ 2,339
Number of common stock shares issued				1,985,754
Shares issued price per share				$ 0.028888
Principal converted value				$ 55,000
First Note and Back-End Note [Member] \| GS Capital Partners LLC [Member] \| Stock Purchase Agreements [Member] \| 90 Days either Note Issuance [Member]
Prepayment amount, percentage		120.00%				120.00%
First Note and Back-End Note [Member] \| GS Capital Partners LLC [Member] \| Stock Purchase Agreements [Member] \| 91 Days either Note Issuance [Member]
Prepayment amount, percentage		133.00%				133.00%
First Note and Back-End Note [Member] \| GS Capital Partners LLC [Member] \| Securities Purchase Agreement [Member] \| 90 Days either Note Issuance [Member]
Prepayment amount, percentage					120.00%
First Note and Back-End Note [Member] \| GS Capital Partners LLC [Member] \| Securities Purchase Agreement [Member] \| 91 Days either Note Issuance [Member]
Prepayment amount, percentage					133.00%
First Note and Back-End Note [Member] \| GS Capital Partners LLC [Member] \| Stock Purchase Agreements [Member]
Accrued interest								1,123		1,123
Convertible Note [Member] \| Individual Note Holders [Member]
Debt principal amount											$ 15,000
Debt instrument, interest rate											8.00%
Accrued interest								$ 7,026		7,026
Debt conversion price per share											$ 1.875
Convertible Note [Member] \| Individual Note Holders [Member] \| October 22, 2018 [Member]
Number of common shares settled for the note, value										$ 25,500
Number of common shares settled for the note										1,000,000

XML 56 R41.htm IDEA: XBRL DOCUMENT

Related Parties (Details Narrative) - USD ($)				6 Months Ended
Related Parties (Details Narrative) - USD ($)	Oct. 06, 2017	Jun. 21, 2017	Jun. 15, 2017	Sep. 30, 2018
Ice + Jam LLC [Member]
Cash collected related party sales				$ 581
Due to related party				$ 5,522
Chief Executive Officer [Member]
Investment	$ 137,500	$ 55,000	$ 95,000
Equity private placement of investment	1,466,667	586,667	1,013,334
Equity investment per share	$ 0.09375	$ 0.09375	$ 0.09375

XML 57 R42.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details Narrative) - USD ($)			6 Months Ended		12 Months Ended
Stockholders' Equity (Details Narrative) - USD ($)	Jun. 27, 2017	Feb. 01, 2012	Sep. 30, 2018	Sep. 30, 2017	Mar. 31, 2018	Mar. 12, 2018	Dec. 22, 2016
Common stock authorized			100,000,000		100,000,000	100,000,000
Common stock, shares outstanding			54,380,230		52,264,476
Contingent liability			$ 75,000		$ 75,000
Stock option granted
GS Capital Partners LLC [Member]
Debt instruments interest rate	5.00%
Debt principal amount	$ 80,000
Stock option granted	213,334
Warrant term	5 years
Warrant exercise price per share	$ 0.2625
Debt discount	$ 12,546
Transfer Agreement [Member] \| Open Therapeutics, LLC [Member]
Membership interest percentage							80.00%
Percentage of unexercised portion of warrant to purchase of shares terminated and cancel during the period							80.00%
Percentage of membership interest sold							20.00%
Contingent liability			$ 75,000				$ 75,000
Percentage of vote membership interest							20.00%
One Current Executive [Member]
Options to purchase common shares		66,667
One Former Executive [Member]
Options to purchase common shares		66,667
Executives [Member]
Options to purchase common shares		133,334
Fiscal Year 2018 [Member]
Number of stock issued during period					1,926,667
Fiscal Year 2018 [Member] \| Individual Note Holders [Member]
Number of stock issued during period					1,133,334
Stock issued during period, per share					$ 0.075
Number of common stock issued					$ 86,600
Fiscal Year 2018 [Member] \| Note Holders [Member]
Number of stock issued during period					20,160,661
Convertible notes payable, net					$ 601,749
Accrued interest					$ 85,055
Fiscal Year 2018 [Member] \| Note Holders [Member] \| Minimum [Member]
Stock issued during period, per share					$ 0.016875
Fiscal Year 2018 [Member] \| Note Holders [Member] \| Maximum [Member]
Stock issued during period, per share					$ 0.09
Fiscal Year 2018 [Member] \| Private Investor [Member]
Number of stock issued during period					1,885,715
Stock issued during period, per share					$ 0.0975
Number of common stock issued					$ 177,500
Fiscal Year 2018 [Member] \| Chief Executive Officer [Member]
Number of stock issued during period					1,600,000
Stock issued during period, per share					$ 0.09375
Number of common stock issued					$ 150,000
Fiscal Year 2018 [Member] \| Debt and Legal Settlement [Member]
Number of stock issued during period					1,553,334
Stock issued during period, per share					$ 0.045
Number of common stock issued					$ 75,050
Fiscal Year 2018 [Member] \| Former Officers and Directors [Member]
Number of stock issued during period					868,000
Stock issued during period, per share					$ 0.2025
Number of common stock issued					$ 173,999
Fiscal Year 2019 [Member]
Stock issued during period, per share			$ 0.028875
Number of common stock issued			$ 57,339
Restricted common stock issued during period			1,985,754
Share-based compensation expense			$ 175,276	$ 503,756
Fiscal Year 2019 [Member] \| Consulting Agreements [Member]
Restricted common stock issued during period			130,000

XML 58 R43.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Schedule of Warrants Activity (Details) - USD ($)	6 Months Ended	12 Months Ended
	Sep. 30, 2018	Mar. 31, 2018
Aggregate Intrinsic Value, Beginning
Aggregate Intrinsic Value, Ending
Warrant [Member]
Shares, Outstanding, Beginning balance	1,433,611	1,220,227
Shares, Granted		213,334
Shares, Expired
Shares, Exercised
Shares, Canceled
Shares, Outstanding, Ending balance	1,433,611	1,433,611
Weighted Average Exercise Price, Outstanding, Beginning balance	$ 1.06	$ 1.50
Weighted Average Exercise Price, Granted		0.2625
Weighted Average Exercise Price, Expired
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Canceled
Weighted Average Exercise Price, Outstanding, Ending balance	$ 1.60	$ 1.06
Weighted Average Remaining Contractual Term, Beginning	3 years 7 days	3 years 1 month 27 days
Weighted Average Remaining Contractual Term, Granted	0 years	4 years 11 months 26 days
Weighted Average Remaining Contractual Term, Ending	2 years 6 months 7 days	3 years 7 days
Aggregate Intrinsic Value, Beginning
Aggregate Intrinsic Value, Ending

XML 59 R44.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Schedule of Assumptions Under Black-Scholes Pricing Model (Details)	6 Months Ended	12 Months Ended
	Sep. 30, 2018	Mar. 31, 2018
Warrant [Member]
Volatility	108.60%	108.60%
Risk-free rate	1.24%	1.24%
Expected dividend rate	0.00%	0.00%
Expected life of option / warrants	5 years	5 years
Stock Options [Member]
Volatility	220.00%
Risk-free rate	1.87%
Expected dividend rate	0.00%
Expected life of option / warrants	10 years

XML 60 R45.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Schedule of Stock Options Activity (Details) - USD ($)	6 Months Ended	12 Months Ended
	Sep. 30, 2018	Mar. 31, 2018
Equity [Abstract]
Number of Options, Outstanding, Beginning balance	133,334	133,334
Number of Options, Granted
Number of Options, Expired
Number of Options, Exercised
Number of Options, Outstanding, Ending balance	133,334	133,334
Weighted Average Exercise Price, Outstanding, Beginning balance	$ 7.50	$ 7.50
Weighted Average Exercise Price, Granted
Weighted Average Exercise Price, Expired
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Outstanding, Ending balance	$ 7.50	$ 7.50
Weighted Average Remaining Contractual Term, Beginning	3 years 10 months 6 days	4 years 10 months 6 days
Weighted Average Remaining Contractual Term, Ending	3 years 4 months 6 days	3 years 10 months 6 days
Aggregate Intrinsic Value, Beginning
Aggregate Intrinsic Value, Ending

XML 61 R46.htm IDEA: XBRL DOCUMENT

Provision for Income Taxes (Details Narrative) - USD ($)		6 Months Ended
	Dec. 22, 2017	Sep. 30, 2018	Mar. 31, 2018
Valuation allowance		$ 29,000	$ 140,000
Income tax examination description	Effective January 1, 2018, the federal tax rate for corporations was reduced from 35% to 21% for US taxable income and requires one-time re-measurement of deferred taxes to reflect their value at a lower tax rate of 21%.
Federal tax rate	21.00%
Untaxed earnings and profit tax rate	15.50%
Tax rate on remaining balance	8.00%
United States [Member]
Net operating loss carryforward		$ 11,000,000
Net operating loss carryforward, expiration year		2038
United States [Member] \| Minimum [Member]
Effective tax rate	28.00%
United States [Member] \| Maximum [Member]
Effective tax rate	30.00%
Canadian [Member]
Net operating loss carryforward		$ 700,000

XML 62 R47.htm IDEA: XBRL DOCUMENT

Provision for Income Taxes - Schedule of Deferred Tax Assets (Details) - USD ($)	Sep. 30, 2018	Mar. 31, 2018
Income Tax Disclosure [Abstract]
Net operating losses	$ 8,543,000	$ 8,514,000
Effect of TCJA recalculation	(3,107,000)	(3,107,000)
Valuation allowance	(5,436,000)	(5,407,000)
Deferred tax assets, net

XML 63 R48.htm IDEA: XBRL DOCUMENT

Investments (Details Narrative) - USD ($)								6 Months Ended	12 Months Ended
Investments (Details Narrative) - USD ($)	Sep. 04, 2018	Aug. 25, 2018	Aug. 20, 2018	Jul. 15, 2018	Jun. 08, 2018	Apr. 02, 2018	Mar. 12, 2018	Sep. 30, 2018	Mar. 31, 2018	Aug. 01, 2017
Reverse stock split					1-for-75		1-for-75	1-for-75
Investment - digital currency									$ 22,056
Conversion of BTC			$ 26,783
Conversion of gold and silver commodities		$ 24,046
Loss on transaction		$ 2,737
Cost investments								$ 15,000
Honeywood Conversion Agreement [Member]
Percentage on membership interest								5.00%
Investment amount								$ 0
Groestlcoin [Member]
Cumulative purchase amount						$ 8,000			$ 35,000
Purchase of units						11,922.81			27,919.133
Purchase of units, price per share						$ 0.6569			$ 0.79
Loss on exchange from BTC									$ 2,859
Cost incurred in investment									31,481
Unrealized loss on digital currency exchange								$ 3,142	9,425
Investment - digital currency									$ 22,056
Sale of units				39,862
Conversion into BTC				4.17
Sale of units value				$ 32,230
AYTU Bioscience [Member] \| Common Stock [Member]
Warrants purchase of common shares								5,555
Warrants strike price								$ 10.80
Warrants expired date								Mar. 06, 2023
Reverse stock split								1 for 20 reverse stock split
AYTU Bioscience [Member] \| Warrant [Member]
Warrants strike price								$ 8.04
VistaGen Therapeutics, Inc. [Member] \| Common Stock [Member]
Warrants purchase of common shares								320,000
Warrants strike price								$ 1.50
Warrants expired date								Dec. 13, 2022
VistaGen Therapeutics, Inc. [Member] \| Warrant [Member]
Warrants strike price								$ 0.05
VistaGen Therapeutics, Inc. [Member] \| Common Stock One [Member]
Warrants purchase of common shares								230,000
Warrants strike price								$ 1.50
Warrants expired date								Feb. 28, 2022
Honeywood [Member]
Percentage on membership interest										5.00%
Kudzoo, Inc. [Member]
Percentage on membership interest	0.20%
Cost investments	$ 15,000
Pre- money valuation amount	$ 7,500,000

XML 64 R49.htm IDEA: XBRL DOCUMENT

Investments - Schedule of Investment in Trading Securities (Details) - USD ($)

6 Months Ended

12 Months Ended

Sep. 30, 2018

Mar. 31, 2018

$ 801,148

$ 250,000

1,612,010

801,148

(1,966,423)

6,815

677,360

801,148

708,296

610,699

230,625

(243,185)

Green Innovations Ltd (GNIN) [Member]

221,385

(190,449)

^[1]

^[2]

250,000

^[3]

^[1]

^[2]

^[3]

^[1]

^[2]

6,815

^[3]

^[1]

^[2]

^[3]

^[1]

^[2]

^[3]

^[1]

^[2]

(243,185)

^[3]

VistaGen Therapeutics, Inc. [Member]

^[1]

^[2]

^[3]

^[4]

490,117

^[4]

349,498

490,117

^[4]

(517,485)

^[4]

287,500

490,117

^[4]

333,500

306,207

^[4]

(34,630)

Blink Charging Co (BLNK) [Member]

^[4]

229,910

(183,910)

^[5]

190,350

^[5]

151,666

190,350

^[5]

(367,142)

^[5]

190,350

^[5]

123,750

^[5]

25,126

Blink Charging Co (BLNKW) (Warrants) [Member]

^[5]

66,600

(66,600)

^[5]

900

^[5]

162,215

900

^[5]

(468,496)

^[5]

900

^[5]

31,545

^[5]

305,381

Aytu BioScience Inc (AYTU) [Member]

^[5]

(30,645)

30,645

^[6]

82,270

^[6]

100,030

82,270

^[6]

(144,094)

^[6]

82,270

^[6]

119,947

^[6]

(38,206)

Lightbridge Corp. (LTBR) [Member]

^[6]

(37,677)

37,677

^[7]

37,511

^[7]

299,028

37,511

^[7]

(114,887)

^[7]

237,198

37,511

^[7]

213,672

29,250

^[7]

15,546

Pulmatrix Inc PULM [Member]

^[7]

(15,265)

$ (8,261)

^[8]

^[8]

204,802

^[8]

(183,737)

^[8]

^[8]

^[8]

(21,065)

Axovant Sciences Ltd AXON [Member]

^[8]

^[9]

^[9]

103,938

^[9]

(98,433)

^[9]

^[9]

^[9]

(5,505)

Paymeon Inc. ("PAYM") [Member]

^[9]

^[10]

^[10]

42,998

^[10]

(10,821)

^[10]

30,000

^[10]

67,960

^[10]

(2,177)

Achieve Life Sciences (ACHV) [Member]

^[10]

37,960

^[11]

^[11]

177,355

^[11]

(44,535)

^[11]

122,249

^[11]

92,909

^[11]

(10,571)

Decision Diagnostics (DECN) [Member]

^[11]

(29,340)

^[12]

^[12]

20,480

^[12]

(16,793)

^[12]

413

^[12]

255

^[12]

(3,274)

^[12]

$ (158)

[1]	During the year ended March 31, 2018, the Company’s investment in Green Innovations, Ltd. was sold for net proceeds of $6,815 and was previously carried as an investment included within Current Assets. The Company’s investment in Green Innovations, Ltd. had a cost of $250,000. A loss of $243,185 was recognized on the sale of this security in the year ended March 31, 2018. For the six months ended September 30, 2018, there was a comprehensive gain recorded of $125.
[2]	There were no trading securities during the quarter ended September 30, 2017
[3]	During the quarter ended December 31, 2017, this security was reclassified from Available for Sale to Trading Security
[4]	On December 11, 2017 the Company invested $480,000 in the common stock of VistaGen Therapeutics, Inc. (VTGN). The Company purchased 320,000 common shares along with 320,000 five-year warrants with a strike price of $1.50. On March 26, 2018, the Company purchased an additional 10,000 common shares. The investment in the common shares is recorded at fair valve with unrealized gains and losses, reflected in other operating income. The Company’s investment in VTGN has a cost of $490,117, unrealized loss of $183,910 and a fair value of $306,207 at March 31, 2018. During the six months ended September 30, 2018, the Company purchased 59,380 shares of VTGN for $61,998 (average price per share of $1.04 per share) in the open market. The Company sold 389,380 shares of VTGN for $517,485 ($1.33 per share) for a realized loss of $34,630. The Company also purchased in a direct offering 230,000 restricted common shares directly from VTGN during the six months ended September 30, 2018 for a cost of $287,500. These shares are currently not on deposit with the Company’s broker of record. As of September 30, 2018 the Company has an unrealized gain on these shares in the amount of $46,000, and for the six months ended September 30, 2018 has recorded total unrealized gains of $229,910 in VTGN.
[5]	The Company participated in an $18,500,250 underwritten public offering by BLINK, which closed on February 14, 2018. The Company invested $191,250 of its balance sheet cash and purchased 45,000 registered shares, as well as warrants exercisable immediately for a period of five (5) years from the date of issuance for up to 90,000 additional shares of common stock of BLINK. The Warrants carry an exercise price of $4.25 per share, and also trade on the NASDAQ under the ticker symbol: BLNKW. The Company’s investment in BLINK common stock and warrants had a cost of $191,250, unrealized loss of $35,955 and a fair value of $155,295 at March 31, 2018. During the three months ended June 30, 2018 the Company purchased 41,018 shares of BLINK at a cost of $151,666 (average price per share of $3.69). The Company sold its total holding of 86,018 shares of BLINK for $367,142 (average price per share of $4.26) realizing a gain of $25,126. During the three months ended June 30, 2018, the Company also purchased 208,800 warrants of BLNKW (average price per warrant of $0.77) and sold its entire position of 298,800 for $468,496 (average price per warrant of $1.60) realizing a gain of $305,381.
[6]	On March 2 and March 8, 2018, the Company purchased 188,300 common shares of AYTU Bioscience (ATYU). The investment in the common shares is recorded at fair valve with unrealized gains and losses, reflected in other operating income. The Company’s investment in ATYU had a cost of $82,270, unrealized gain of $37,677 and a fair value of $119,947 at March 31, 2018. During the six months ended September 30, 2018, the Company purchased 260,000 shares of AYTU for a $100,830 (average price per share $0.38). During the six months ended September 30, 2018, the Company sold all 448,300 shares of AYTU for $144,094 ($0.32 per share). During the six months ended September 30, 2018, the Company had a realized loss of $38,206 on this holding.
[7]	On March 12, 2018, the Company purchased 25,000 common shares of Lightbridge Corp (LTBR). The investment in the common shares is recorded at fair valve with unrealized gains and losses, reflected in other operating income. The Company’s investment in LTBR had a cost of $37,511, unrealized loss of $8,261 and a fair value of $29,250 at March 31, 2018. During the six months ended September 30, 2018, the Company purchased 287,405 shares of LTBR for $299,028 (average of $1.04 per share.) During the six months ended September 30, 2018, the Company sold 80,405 shares of LTBR for $114,887 (average price per share of $1.43) realizing a gain of $15,456. As of September 30, 2018, the Company has an unrealized loss of $23,526 on this holding, and for the six months ended September 30, 2018 has recorded total unrealized losses of $15,265 in LTBR.
[8]	During the six months ended September 30, 2018, the Company purchased 391,514 shares of Pulmatix Inc. (PULM) for $204,802 (average per share price of $0.52). During the six months ended September 30, 2018, the Company sold all 391,514 shares for $183,747 ($0.47 per share). The Company had a realized loss of $21,065 on this holding.
[9]	During the six months ended September 30, 2018, the Company purchased 40,000 shares of Axovant Sciences Ltd. (AXON) for $103,938 (average share price of $2.60). During the six months ended September 30, 2018, the Company sold all 40,000 shares for $98,433 ($2.46 per share). The Company had a realized loss of $5,505 on this holding.
[10]	On July 5, 2018, the Company purchased 100,000 shares of Paymeon, Inc. (PAYM) for $12,998 ($0.13 per share) in the open market. During July 2018 the Company sold the 100,000 shares for $10,821 ($0.11 per share) for a realized loss of $2,177. On July 9, 2018, the Company purchased 400,000 restricted common shares directly from the Company for $30,000 ($0.075 per share). As of September 30, 2018 the Company had an unrealized gain of $37,960 on these shares. In conjunction with the investment, the Company agreed to a 12-month resale restriction. PAYM is publicly traded on the OTC:Pink. These shares are currently not on deposit held with the Company’s broker of record.
[11]	During the six months ended September 30, 2018, the Company purchased 44,000 common shares of Achieve Life Sciences (ACHV) for $177,355 ($4.03 per share). During the six months ended September 30, 2018, the Company sold 14,505 shares for $44,535 ($3.07 per share) for a realized loss of $10,571. At September 30, 2018, the Company has an unrealized loss on its remaining holdings in ACHV in the amount of $29,340.
[12]	During the six months ended September 30, 2018, the Company purchased 450,000 common shares of Decision Diagnostics (DECN) for $20,480 ($0.046 per share). During the six months ended September 30, 2018, the Company sold 441,500 shares for $16,793 ($0.038 per share) for a realized loss of $3,274. At September 30, 2018, the Company has an unrealized loss on its remaining holdings in DECN in the amount of $158.

XML 65 R50.htm IDEA: XBRL DOCUMENT

Investments - Schedule of Investment in Trading Securities (Details) (Parenthetical) - USD ($)

1 Months Ended

3 Months Ended

6 Months Ended

12 Months Ended

Jul. 09, 2018

Jul. 05, 2018

Mar. 26, 2018

Mar. 12, 2018

Mar. 08, 2018

Mar. 02, 2018

Feb. 14, 2018

Dec. 11, 2017

Jul. 31, 2018

Sep. 30, 2018

Jun. 30, 2018

Sep. 30, 2017

Sep. 30, 2018

Sep. 30, 2017

Mar. 31, 2018

$ 1,966,423

$ (6,815)

$ 801,148

801,148

250,000

(109,395)

230,625

Comprehensive gain

(263,085)

(655,596)

(98,764)

(1,504,116)

677,360

801,148

143,215

221,385

Green Innovations Ltd (GNIN) [Member]

708,296

610,699

^[1]

^[2]

(6,815)

^[3]

^[1]

^[2]

250,000

^[3]

243,185

Comprehensive gain

$ 125

^[1]

^[2]

^[3]

VistaGen Therapeutics, Inc. [Member]

^[1]

^[2]

^[3]

^[4]

517,485

^[4]

490,117

$ 229,910

59,380

^[4]

287,500

$ 287,500

490,117

34,630

183,910

^[4]

$ 333,500

333,500

306,207

$ 61,998

$ 1.04

389,380

$ 517,485

VistaGen Therapeutics, Inc. [Member] | Restricted Common Stock [Member]

$ 1.33

$ 46,000

230,000

VistaGen Therapeutics, Inc. [Member] | Common Stock [Member]

$ 287,500

$ 480,000

Warrants purchase of common shares

320,000

320,000

Warrant term

5 years

Warrants strike price

$ 1.50

Additional number of common stock purchased

10,000

Blink Charging Co (BLNK) [Member]

^[5]

367,142

^[5]

$ 190,350

190,350

^[5]

190,350

Participated in underwritten public offering amount

^[5]

123,750

$ 18,500,250

Blink Charging Co (BLNK) [Member] | Warrants [Member]

191,250

35,955

Blink Charging Co (BLNK) [Member] | Balance Sheet Cash [Member]

155,295

Blink Charging Co (BLNK) [Member] | Common Stock [Member]

$ 191,250

$ 25,126

Warrants purchase of common shares

41,018

208,800

45,000

Warrant term

5 years

Warrants strike price

$ 0.77

$ 4.25

$ 151,666

$ 3.69

86,018

$ 367,142

Sale of warrants purchased

$ 4.26

298,800

Sale of warrant purchased value

$ 468,496

Blink Charging Co (BLNK) [Member] | Common Stock [Member] | Maximum [Member]

Additional number of common stock purchased

90,000

Blink Charging Co (BLNK) [Member] | Warrant [Member]

Aytu BioScience Inc (AYTU) [Member]

$ 305,381

Warrants strike price

$ 1.60

^[6]

144,094

^[6]

82,270

$ 38,206

260,000

^[6]

82,270

^[6]

119,947

$ 100,830

$ 0.38

448,300

$ 144,094

Aytu BioScience Inc (AYTU) [Member] | Common Stock [Member]

$ 0.32

188,300

Lightbridge Corp. (LTBR) [Member]

37,677

^[7]

$ 114,887

^[7]

$ 37,511

37,511

$ 15,456

287,405

^[7]

237,198

$ 237,198

37,511

15,265

8,261

^[7]

$ 213,672

213,672

$ 29,250

$ 299,028

$ 1.04

80,405

$ 114,887

Unrealized loss on holding

1.43

$ 1.43

$ 23,526

Lightbridge Corp. (LTBR) [Member] | Common Stock [Member]

Pulmatix Inc PULM [Member]

25,000

$ 21,065

391,514

$ 204,802

0.52

$ 0.52

391,514

$ 183,747

Axovant Sciences Ltd AXON [Member]

$ 0.47

^[8]

$ 98,433

^[8]

$ 5,505

40,000

^[8]

^[8]

$ 103,938

$ 2.60

40,000

$ 98,433

Paymeon Inc. ("PAYM") [Member]

$ 2.46

^[9]

$ 10,821

^[9]

$ 2,177

100,000

^[9]

30,000

37,960

^[9]

67,960

$ 12,998

$ 0.13

100,000

$ 10,821

Paymeon Inc. ("PAYM") [Member] | Restricted Common Stock [Member]

$ 0.11

400,000

$ 30,000

Achieve Life Sciences (ACHV) [Member]

$ 0.075

^[10]

44,535

^[10]

$ 10,571

44,000

^[10]

122,249

$ 122,249

^[10]

$ 92,909

92,909

$ 177,355

$ 4.03

14,505

$ 44,535

Unrealized loss on holding

$ 3.07

$ 29,340

Decision Diagnostics (DECN) [Member]

^[11]

16,793

^[11]

$ 3,274

450,000

^[11]

413

$ 413

^[11]

$ 255

255

$ 20,480

$ 0.046

441,500

$ 16,793